

CORRECTED VERSION

10/528673

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029267 A1

(51) International Patent Classification⁷: C12P 17/04, 7/58

(21) International Application Number:

PCT/EP2003/010489

(22) International Filing Date:

22 September 2003 (22.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

02021602.4 27 September 2002 (27.09.2002) EP

(71) Applicant (for all designated States except US): DSM IP
ASSETS B.V. [NL/NL]; Het Overloon 1, NL-6411 TE
Heerlen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HOSHINO, Tatsuo
[JP/JP]; 2-18-14, Fueta, Kamakura-shi, Kanagawa-ken
248-0027 (JP). SHINJOH, Masako [JP/CH]; Ruemelin-
bachweg 25, Ch-4054 Basel (CH).

(74) Agent: SCHWANDER, Kuno, Josef; Roche Vita-
mins Ltd., Patent Department (VMD), Wurmisweg 576,
CH-4303 Kaiseraugst (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:

3 June 2004

(15) Information about Correction:

see PCT Gazette No. 23/2004 of 3 June 2004, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR PRODUCING L-ASCORBIC ACID

(57) Abstract: The present invention provides the use of Enzyme B of *G. oxydans* DSM 4025, as disclosed in EP 0 832 974 A2, in a process for producing L-ascorbic acid from L-gulose, L-galactose, L-idose or L-talose, or from L-gulonono-1,4-lactone (and its acid form, L-gulononic acid) and from L-galactono-1,4-lactone (and its acid form, L-galactonic acid).

WO 2004/029267 A1

Process for producing L-ascorbic acid

The present invention relates to the use of Enzyme B of *Gluconobacter oxydans* DSM 4025 as disclosed in EP 0 832 974 A2 in a process for producing L-ascorbic acid.

Feasibility studies on the biotechnological synthesis of L-ascorbic acid (vitamin C) were performed for many years since the "Reichstein method" was established in 1934.

5 The microorganisms *Gluconobacter oxydans* DSM 4025 or *Escherichia coli* carrying the D-arabinono-1,4-lactone oxidase gene of *Saccharomyces cerevisiae*, *Candida albicans* and *Saccharomyces cerevisiae* oxidize L-galactono-1,4-lactone to vitamin C. *Saccharomyces cerevisiae* and *Candida albicans* possess a D-arabinose dehydrogenase catalyzing the production of D-arabinono-1,4-lactone and L-galactono-1,4-lactone from D-arabinose
10 and L-galactose, respectively. However, there were no reports describing the possibility of biological vitamin C production from another L-hexose as intermediate, that is, L-idose, L-gulose, and L-talose, with a configuration corresponding to that of vitamin C (C4 and C5 positions):

The present invention provides the use of Enzyme B of *G. oxydans* DSM 4025, as
15 disclosed in EP 0 832 974 A2, in a process for producing L-ascorbic acid from L-gulose, L-galactose, L-idose or L-talose, or from L-gulono-1,4-lactone (and its acid form, L-gulonic acid) and from L-galactono-1,4-lactone (and its acid form, L-galactonic acid).

The present invention also provides the use of Enzyme B of *G. oxydans* DSM 4025, as disclosed in EP 0 832 974 A2, in a process for producing L-gulono-1,4-lactone or L-
20 galactono-1,4-lactone, or their acid forms L-gulonic acid or L-galactonic acid from L-gulose or L-galactose, respectively.

EP 0 832 974 A2, which is incorporated by reference, discloses Enzyme B of *G. oxydans* DSM 4025 having the following physico-chemical properties:

- (a) molecular weight of about 60,000 Da on SDS-PAGE;
- 25 (b) substrate specificity for primary and secondary alcohols and aldehydes;
- (c) pH-stability at pH of about 6 to about 9;
- (d) pH-optimum at pH of about 8.0; and
- (e) inhibited by Cu^{2+} , Zn^{2+} , Mn^{2+} , Fe^{2+} , and Fe^{3+} .

Furthermore, the amino acid sequences as well as the nucleotide sequences of Enzyme B are disclosed in EP 0 832 974 A2 and represented by SEQ ID NO: 2 and SEQ ID NO: 1 of the present sequence listing. It is known from EP 0 832 974 A2 that Enzyme B is able to convert D-glucose, D-sorbitol, L-sorbose, D-mannitol, L-idose, glycerol, D-gluconic acid, D-mannonic acid to D-gluconate, L-sorbose, 2-KGA, D-fructose, L-idonic acid, dihydroxyacetone, 5-keto-D-gluconic acid, and 5-keto-D-mannonic acid, respectively.

The present invention is related to a process for the production of L-ascorbic acid with an enzyme having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-ascorbic acid, whereby L-ascorbic acid is produced from a substrate which is selected from the group consisting of L-gulose, L-galactose, L-idose, and L-talose.

L-Hexoses like L-gulose, L-galactose, L-idose, and L-talose are rare sugars which are basically produced by chemical methods and are commercially high-cost compounds. However, biological preparations for L-gulose and L-galactose have been recently reported. L-Gulose production from D-sorbitol by Enzyme A of *G. oxydans* DSM 4025 was reported in EP 0 832 974 A2. L-Gulose production from L-sorbose by L-ribose isomerase was disclosed in US 6,037,153. L-Galactose production from L-sorbose is reported by Izumori et al. (2001 Annual Meeting of the Society for Bioscience and Bioengineering, Japan). In this process they combined two enzymatic processes consisting of "L-sorbose to L-tagatose" reaction with L-tagatose epimerase of *Pseudomonas cichorii* ST-24 strain (US 5,811,271) and "L-tagatose to L-galactose" reaction with D-arabinose isomerase of *Bacillus stearothermophilus* 14a strain. L-Gulonono-1,4-lactone may be prepared from D-glucose.

In another aspect the present invention provides a process for

- (a) producing
 - (i) L-ascorbic acid from L-gulose or L-galactose by an enzyme which comprises contacting L-gulose or L-galactose with an enzyme having an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, or a portion thereof, with the activity to produce L-ascorbic acid from L-gulose and L-galactose or a functional equivalent thereof, in a reaction mixture,
 - (ii) L-gulonono-1,4-lactone from L-gulose, or L-galactono-1,4-lactone from L-galactose by an enzyme which comprises contacting L-gulose or L-galactose with an enzyme having an amino acid sequence of SEQ ID NO:2 or an amino acid sequence that is 90% identical thereto, or a portion thereof, with the activity to produce L-gulonono-1,4-lactone from L-gulose and L-galactono-1,4-lactone from L-galactose, or a functional equivalent thereof, in a reaction mixture, or

- (iii) L-ascorbic acid from L-gulono-1,4-lactone or from L-galactono-1,4-lactone by an enzyme which comprises contacting L-gulono-1,4-lactone or from L-galactono-1,4-lactone with the enzyme having an amino acid sequence of SEQ IDNO: 2 or an amino acid sequence that is 90% identical thereto, or a portion thereof, with the activity to produce L-ascorbic acid from L-gulono-1,4-lactone and from L-galactono-1,4-lactone, or a functional equivalent thereof, in a reaction mixture, and
- (b) isolating L-ascorbic acid, L-gulono-1,4-lactone or L-galactono-1,4-lactone from the reaction mixture.

- 10 It is one embodiment of the present invention to provide a process for the production of L-ascorbic acid with an enzyme having the amino acid sequence of SEQ IDNO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-ascorbic acid, whereby L-ascorbic acid is produced from a substrate which is selected from the group consisting of L-gulono-1,4-lactone, L-gulonic acid, L-galactono-1,4-lactone, L-galactonic acid, L-idono-1,4-lactone, L-idonic acid, L-talono-1,4-lactone, and L-talonic acid.

- In a further embodiment, the present invention covers a process for the production of L-gulono-1,4-lactone or L-gulonic acid with an enzyme having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-gulono-1,4-lactone or L-gulonic acid, whereby L-gulono-1,4-lactone or L-gulonic acid is produced from L-gulose.

- Furthermore, it is an aspect of the present invention to provide a process for the production of L-galactono-1,4-lactone or L-galactonic acid with an enzyme having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-galactono-1,4-lactone or L-galactonic acid, whereby L-galactono-1,4-lactone or L-galactonic acid is produced from L-galactose.

- A process according to the present invention as described above comprises (a) contacting the enzyme with the respective substrate and (b) isolating the respective product from the reaction mixture. In case of vitamin C as product, the substrate is selected from the group consisting of L-gulose, L-galactose, L-idose, L-talose, L-gulono-1,4-lactone, L-gulonic acid, L-galactono-1,4-lactone, L-galactonic acid, L-idono-1,4-lactone, L-idonic acid, L-talono-1,4-lactone, and L-talonic acid. In case of L-gulono-1,4-lactone or L-gulonic acid as product, the substrate is L-gulose. In case of L-galactono-1,4-lactone or L-galactonic acid as product, the substrate is L-galactose.

In the present invention, a functional equivalent of the enzyme can be made either by chemical peptide synthesis known in the art or by recombinant means on the basis of the DNA sequences as disclosed herein by methods known in the state of the art. Amino acid exchanges in proteins and peptides which do not generally alter the activity of such molecules are known in the state of the art. The most commonly occurring exchanges are: Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly as well as these in reverse.

Furthermore such functional equivalent of the enzyme includes an amino acid sequence encoded by a DNA sequence of SEQ ID NO: 1 as disclosed, e.g., in the sequence listing as well as the complementary strand, or those which include the sequences, DNA sequences which hybridize under standard conditions with such sequences or fragments thereof and DNA sequences, which because of the degeneration of the genetic code, do not hybridize under standard conditions with such sequences but which code for polypeptides having exactly the same amino acid sequence, wherein the functional equivalent has the enzymatic activity of producing

- (i) L-ascorbic acid from L-gulose and from L-galactose,
- (ii) L-gulono-1,4-lactone (and its acid form, L-gulonic acid) from L-gulose and L-galactono-1,4-lactone (and its acid form, L-galactonic acid) from L-galactose, or
- (iii) L-ascorbic acid from L-gulono-1,4-lactone (and its acid form, L-gulonic acid) and from L-galactono-1,4-lactone (and its acid form, L-galactonic acid).

"Standard conditions" for hybridization mean in this context the conditions which are generally used by a man skilled in the art to detect specific hybridization signals, or preferably so called stringent hybridization and non-stringent washing conditions or more preferably so called stringent hybridization and stringent washing conditions a man skilled in the art is familiar with. Furthermore, DNA sequences which can be made by the polymerase chain reaction by using primers designed on the basis of the DNA sequences disclosed herein by methods known in the art are also an object of the present invention. It is understood that the DNA sequences of the present invention can also be made synthetically as described, e.g. in EP 747 483 A2.

A mutant of the gene can be prepared by treating the gene or a microorganism carrying the gene with a mutagen such as ultraviolet irradiation, X-ray irradiation, γ -ray irradiation or contact with a nitrous acid, N-methyl-N'-nitro-N-nitrosoguanidine (NTG), or other suitable mutagens, or isolating a colony or clone occurring by spontaneous mutation or by standard methods of *in vitro* mutagenesis known in the art. Many of these methods have been described in various publications.

As used herein, a "mutant" is any gene that encodes a non-native polynucleotide sequence or a polynucleotide sequence that has been altered from its native form (such as, e.g., by rearrangement or deletion or substitution of from 1-100, preferably 20-50, more preferably less than 10 nucleotides). As noted above, such a non-native sequence may be obtained by random mutagenesis, chemical mutagenesis, spontaneous mutation, UV-irradiation, PCR-prone error generation, site-directed mutagenesis, and the like. Preferably, the mutation results in the expression of a polypeptide having the increased production or improved activity compared to a non-mutant parental polypeptide using the assay procedures set forth in the Examples. Methods for generating, screening for, and identifying such mutant cells are well known in the art.

A specific and preferred *G. oxydans* strain as a donor of a DNA sequence encoding a polypeptide has been deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) in Göttingen (Germany) under DSM No. 4025, which was done under the stipulations of the Budapest Treaty on March 17, 1987. A biologically and/or taxonomically homogeneous culture of a microorganism having the identifying characteristics *G. oxydans* DSM 4025 can also be a donor of the DNA sequence.

A subculture of *G. oxydans* DSM 4025 has been deposited in the Agency of Industrial Science and Technology, Fermentation Research Institute, Japan, under the deposit No.: FERM BP-3812. EP 0 278 447 B1 discloses the characteristics of this strain.

By using the information of the so determined nucleotide sequence (in consideration of the codon usage) a gene encoding evolutionally divergent enzyme having the activity of producing (i) L-ascorbic acid from L-gulose and L-galactose, (ii) L-gulono-1,4-lactone (and its acid form, L-gulonic acid) from L-gulose and L-galactono-1,4-lactone (and its acid form, L-galactonic acid) from L-galactose, or (iii) L-ascorbic acid from L-gulono-1,4-lactone (and its acid form, L-gulonic acid) and from L-galactono-1,4-lactone (and its acid form, L-galactonic acid), vitamin C forming-activity from L-gulose or L-galactose, can be isolated from a different organism by colony- or Southern-hybridization with a probe synthesized according to the amino acid sequence deduced from said nucleotide sequence or by the polymerase chain reaction with primers also synthesized according to said information, if necessary.

Furthermore, a preferred host microorganism for constructing a recombinant microorganism carrying Enzyme B gene of *G. oxydans* DSM 4025 and its functional equivalent or mutant defined above may be *Escherichia coli*, *Pseudomonas putida* and *G. oxydans* DSM 4025 and their biologically and/or taxonomically homogeneous culture or mutant.

To construct a recombinant microorganism carrying the gene for Enzyme B and its functional equivalent or mutant on a recombinant expression vector or on a chromosomal DNA of a host microorganism, various gene transfer methods including transformation, transduction, conjugal mating, and electroporation can be used. The method for constructing a recombinant organism may be selected from the methods well known in the field of molecular biology. Usual transformation systems can be used for *Escherichia coli*, and *Pseudomonas*. A transduction system can also be used for *Escherichia coli*. Conjugal mating systems can be widely used in Gram-positive and Gram-negative bacteria including *E. coli*, *Pseudomonas putida* and *G. oxydans*. The conjugation can occur in liquid media or on a solid surface. The preferred recipient is selected from *E. coli*, *Pseudomonas putida* and *G. oxydans* which can produce active Enzyme B with a suitable recombinant expression vector. To the recipient for conjugal mating, a selective marker is usually added; for example, resistance against nalidixic acid or rifampicin is usually selected.

The microorganisms provided in the present invention may be cultured in an aqueous medium supplemented with appropriate nutrients under aerobic conditions. The cultivation may be conducted at a pH between about 1.0 and about 9.0, preferably between about 2.0 and about 8.0. While the cultivation period varies depending upon pH, temperature and nutrient medium used, usually 2 to 5 days will bring about favorable results. A suitable temperature range for carrying out the cultivation is from about 13°C to about 45°C, preferably from about 18°C to about 42°C.

Thus, the process for the production of vitamin C of the present invention as described above is conducted for 1 to 120 h at a pH of about 1 to about 9 and at a temperature of about 13°C to about 45°C. Preferably, the process is conducted at a pH of about 2 to about 8 and at a temperature of about 13°C to about 45°C. These conditions are also applied to the process for the production of L-gulono-1,4-lactone, L-gulonic acid, L-galactono-1,4-lactone or L-galactonic acid, as further embodiments of the present invention.

It is usually required that the culture medium contains such nutrients as assimilable carbon sources, digestible nitrogen sources and inorganic substances, vitamins, trace elements and other growth promoting factors. Examples for assimilable carbon sources include glycerol, D-glucose, D-mannitol, D-fructose, D-arabitol, D-sorbitol and L-sorbose.

Various organic or inorganic substances may also be used as nitrogen sources, such as yeast extract, meat extract, peptone, casein, corn steep liquor, urea, amino acids, nitrates, ammonium salts and the like. As inorganic substances, magnesium sulfate,

potassium phosphate, ferrous and ferric chlorides, calcium carbonate and the like may be used.

As used herein, L-ascorbic acid means that the substance exists either as a free acid form or as a salt form such as Na-salt, K-salt, or hemicalcium-salt, such as calcium L-ascorbate dihydrate. Moreover, concentration of L-ascorbic acid is described as the free acid form unless otherwise stated.

As used herein, L-gulono-1,4-lactone and L-galactono-1,4-lactone mean that the substances exist as their lactone forms and/or their acid forms, both of which exist in an equilibrium state under various physico-chemical conditions.

As used herein the phrase "standard conditions for hybridization" means conditions which are generally used by a person skilled in the art to detect specific hybridization signals, or preferably, so called stringent hybridization and non-stringent washing conditions, or more preferably, so called moderately stringent conditions, or even more preferably, so called stringent hybridization and stringent washing conditions which a person skilled in the art is familiar with.

For example, any combination of the following hybridization and wash conditions may be used, as appropriate:

High Stringency Hybridization: 6X SSC, 0.5% SDS, 100 µg/ml denatured salmon sperm DNA, 50% formamide, incubate overnight at 42°C with gentle rocking.

High Stringency Wash: 1 wash in 2X SSC, 0.5% SDS at room temperature for 15 minutes, followed by another wash in 0.1X SSC, 0.5% SDS at room temperature for 15 minutes.

Low Stringency Hybridization: 6X SSC, 0.5% SDS, 100 µg/ml denatured salmon sperm DNA, 50% formamide, incubate overnight at 37°C with gentle rocking.

Low Stringency Wash: 1 wash in 0.1X SSC, 0.5% SDS at room temperature for 15 minutes.

Moderately stringent conditions may be obtained by varying the temperature at which the hybridization reaction occurs and/or the wash conditions as set forth above.

The concentration of the substrates including L-aldose and L-alDONOLactone in a reaction mixture can vary depending on other reaction conditions, but, in general, may be between about 1 g/l and about 300 g/l, preferably between about 10 g/l and about 200g/l.

The reaction can be conducted aerobically.

For the reaction, the enzyme can be used in any form, including, but not limited to, enzyme solution, immobilized enzyme, intact cells, and immobilized cells may be used.

After the reaction, L-ascorbic acid or L-aldonolactone may be recovered from the reaction mixture by the combination of various kinds of chromatography, for example, thin layer chromatography, adsorption chromatography, ion-exchange chromatography, gel filtration chromatography or high performance liquid chromatography. L-Aldonolactone as a reaction product can also be used as a substrate for a further reaction as it is in the reaction mixture of this invention without purification.

The following examples are provided to further illustrate the process of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.

Example 1: Production of L-gulono-1,4-lactone/L-gulonic acid from L-gulose by *Escherichia coli* JM109 carrying the Enzyme B gene

The gene encoding Enzyme B was cloned and subcloned from pSS103R into a vector pTrcMalE to construct pTrcMalE-EnzB as described in EP 0 832 974 A2. *Escherichia coli* JM109 carrying pTrcMalE-EnzB was grown on 2 ml of LB medium with 100 µg/ml of ampicillin at 30°C for 15 h and 100 µl of the resulting broth was transferred into fresh LB medium with 100 µg/ml of ampicillin and incubated at 30°C for 4 h. Then, IPTG was added to the culture at a final concentration of 0.2 mM and the culture was further cultivated at 30°C for 2 h. The control cultivation of *E. coli* JM109 carrying pTrcMalE-EnzB without IPTG addition was also performed. *Escherichia coli* JM109 was used as the control strain in the same manner as described above, cultivation with or without addition of IPTG. The cells from 8 ml of the culture were collected by centrifugation and suspended in 1 ml of distilled water. The resulting cell suspension was used for the reaction with 400 µl of reaction mixture consisting of 250 µl of the cell suspension, 1% substrate, 0.3% NaCl, 1% CaCO₃, 1 µg/ml of PQQ and 1 mM PMS and the mixture was incubated at room temperature for 16 h. The substrate used in this experiment was L-gulose. The amounts of L-gulono-1,4-lactone plus L-gulonic acid and vitamin C are summarized in Table 1.

Table 1

Strain	IPTG	HPLC	
		L-GuL+L-GuA (mM)	Vitamin C (mg/L)
JM109 /pTrcMalE-EnzB	+	8.4	42.5
	-	4.6	10.5
JM109	+	nd	nd
	-	nd	nd

L-GuL: L-gulono-1,4-lactone; L-GuA: L-gulonic acid; nd: not detected

5 **Example 2: Production of vitamin C from L-gulono-1,4-lactone/L-gulonic acid by *Escherichia coli* JM109 carrying the Enzyme B gene**

The experiment was performed as described in Example 1, except for the substrate used which was L-gulono-1,4-lactone in this Example. The amount of vitamin C is summarized in Table 2.

Table 2

Strain	IPTG	HPLC
		Vitamin C (mg/L)
JM109 /pTrcMalE-EnzB	+	1.4
	-	1.2
JM109	+	nd
	-	nd

10 nd: not detected

Example 3: Production of L-galactono-1,4-lactone/L-galactonic acid from L-galactose by *Escherichia coli* JM109 carrying the Enzyme B gene

15 The experiment was performed as described in Example 1, except for the substrate used which was L-galactose in this Example. The amounts of L-galactono-1,4-lactone plus L-galactonic acid and vitamin C are summarized in Table 3.

Table 3

Strain	IPTG	HPLC	
		L-GaL+L-GaA (mM)	Vitamin C (mg/L)
JM109 /pTrcMalE-EnzB	+	6.2	2.7
	-	3.9	1.6
JM109	+	nd	nd
	-	nd	nd

L-GaL: L-galactono-1,4-lactone; L-GaA: L-galactonic acid; nd: not detected

5 **Example 4:** Production of vitamin C from L-galactono-1,4-lactone/L-galactonic acid
by *Escherichia coli* JM109 carrying the Enzyme B gene

The experiment was performed as described in Example 1, except for the substrate used which was L-galactono-1,4-lactone in this Example. The amount of vitamin C is summarized in Table 4.

Table 4

Strain	IPTG	HPLC
		Vitamin C (mg/L)
JM109 /pTrcMalE-EnzB	+	4.7
	-	3.7
JM109	+	nd
	-	nd


10 nd: not detected

BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

The Oriental Scientific
Instruments, Import and Export
Corp. for Inst. of Microbiology
Academia Sinica
52 San-Li-He Rd.
Beijing, P.R. China

VIABILITY STATEMENT
issued pursuant to Rule 10.2 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

I. DEPOSITOR		II. IDENTIFICATION OF THE MICROORGANISM	
Name: The Oriental Scientific Instruments, Import and Export Address: Corp. for Inst. of Microbiology Academia Sinica 52 San-Li-He Rd. Beijing, P.R. China		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 4025 Date of the deposit or the transfer ¹ : 1987-03-17	
III. VIABILITY STATEMENT			
The viability of the microorganism identified under II above was tested on 2003-08-13 On that date, the said microorganism was (<input checked="" type="checkbox"/>) ² viable () ² no longer viable			
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED ⁴			
V. INTERNATIONAL DEPOSITARY AUTHORITY			
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 2003-08-15	

- ¹ Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).
² In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.
³ Mark with a cross the applicable box.
⁴ Fill in if the information has been requested and if the results of the test were negative.

Claims

1. A process for the production of L-ascorbic acid with an enzyme having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-ascorbic acid, whereby L-ascorbic acid is produced from a substrate which is selected from the group consisting of L-gulose, L-galactose, L-idose, and L-talose.
2. A process for the production of L-ascorbic acid with an enzyme having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-ascorbic acid, whereby L-ascorbic acid is produced from a substrate which is selected from the group consisting of L-gulono-1,4-lactone, L-gulonic acid, L-galactono-1,4-lactone, L-galactonic acid, L-idono-1,4-lactone, L-idonic acid, L-talono-1,4-lactone, and L-talonic acid.
3. A process for the production of L-gulono-1,4-lactone or L-gulonic acid with an enzyme having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-gulono-1,4-lactone or L-gulonic acid, whereby L-gulono-1,4-lactone or L-gulonic acid is produced from L-gulose.
4. A process for the production of L-galactono-1,4-lactone or L-galactonic acid with an enzyme having the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence that is 90% identical thereto, with the activity to produce L-galactono-1,4-lactone or L-galactonic acid, whereby L-galactono-1,4-lactone or L-galactonic acid is produced from L-galactose.
5. A process according to any one of claims 1 to 4 comprising (a) contacting the enzyme with the respective substrate and (b) isolating the product which is selected from the group consisting of L-ascorbic acid, L-gulono-1,4-lactone, L-gulonic acid, L-galactono-1,4-lactone, and L-galactonic acid from the reaction mixture.
6. A process according to any one of claims 1 to 5, wherein the process is conducted for 1 to 120 h at a pH of about 1 to about 9 and at a temperature of about 13°C to about 45°C.
7. A process according to claim 6, wherein the process is conducted at a pH of about 2 to about 8 and at a temperature of about 18°C to about 42°C.
8. Use of Enzyme B of *G. oxydans* DSM 4025 in a process for producing L-ascorbic acid from a substrate which is selected from the group consisting of L-gulose, L-galactose, L-idose, L-talose, L-gulono-1,4-lactone, L-gulonic acid, L-galactono-1,4-lactone, and L-

galactonic acid; wherein Enzyme B has the following physico-chemical properties:

- (a) molecular weight of about 60,000 Da on SDS-PAGE;
- (b) substrate specificity for primary and secondary alcohols and aldehydes;
- (c) pH-stability at pH of about 6 to about 9;
- 5 (d) pH-optimum at pH of about 8.0; and
- (e) inhibited by Cu^{2+} , Zn^{2+} , Mn^{2+} , Fe^{2+} , and Fe^{3+} .

9. Use of Enzyme B of *G. oxydans* DSM 4025 in a process for producing L-gulono-1,4-lactone or L-gulonic acid from L-gulose, wherein Enzyme B has the following physico-chemical properties:

- 10 (a) molecular weight of about 60,000 Da on SDS-PAGE;
- (b) substrate specificity for primary and secondary alcohols and aldehydes;
- (c) pH-stability at pH of about 6 to about 9;
- (d) pH-optimum at pH of about 8.0; and
- (e) inhibited by Cu^{2+} , Zn^{2+} , Mn^{2+} , Fe^{2+} , and Fe^{3+} .

15 10. Use of Enzyme B of *G. oxydans* DSM 4025 in a process for producing L-galactono-1,4-lactone or galactonic acid from L-galactose, wherein Enzyme B has the following physico-chemical properties:

- (a) molecular weight of about 60,000 Da on SDS-PAGE;
- (b) substrate specificity for primary and secondary alcohols and aldehydes;
- 20 (c) pH-stability at pH of about 6 to about 9;
- (d) pH-optimum at pH of about 8.0; and
- (e) inhibited by Cu^{2+} , Zn^{2+} , Mn^{2+} , Fe^{2+} , and Fe^{3+} .

Sequence Listing

<110> Roche Vitamins AG
 <120> Ascorbic Acid Production
 5 <130> Case 21409
 <150> EP 02021602
 10 <151> 2002-09-27
 <160> 2
 <170> PatentIn version 3.2
 15 <210> 1
 <211> 1740
 <212> DNA
 <213> Gluconobacter oxydans
 20
 <220>
 <221> CDS
 <222> (1)..(1740)
 25 <400> 1
 atg aac ccc aca acg ctg ctt cgc acc agc gcg gcc gtg cta ttg ctt 48
 Met Asn Pro Thr Thr Leu Leu Arg Thr Ser Ala Ala Val Leu Leu Leu
 1 5 10 15
 30 acc gcg ccc gcc gca ttc gcg cag gta acc ccg att acc gat gaa ctg 96
 Thr Ala Pro Ala Ala Phe Ala Gln Val Thr Pro Ile Thr Asp Glu Leu
 20 25 30
 35 ctg gcg aac ccg ccc gct ggt gaa tgg att aac tac ggc cgc aac caa 144
 Leu Ala Asn Pro Pro Ala Gly Glu Trp Ile Asn Tyr Gly Arg Asn Gln
 35 40 45
 40 gaa aac tat cgc cac tcg ccc ctg acc cag atc act gcc gac aac gtt 192
 Glu Asn Tyr Arg His Ser Pro Leu Thr Gln Ile Thr Ala Asp Asn Val
 50 55 60
 45 ggt cag ttg caa ctg gtc tgg gcc cgc ggg atg gag gcg ggg gcc gta 240
 Gly Gln Leu Gln Leu Val Trp Ala Arg Gly Met Glu Ala Gly Ala Val
 65 70 75 80
 50 cag gtc acg ccg atg atc cat gat ggc gtg atg tat ctg gca aac ccc 288
 Gln Val Thr Pro Met Ile His Asp Gly Val Met Tyr Leu Ala Asn Pro
 85 90 95
 55 ggt gat gtg atc cag gcg ctg gat gcg caa aca ggc gat ctg atc tgg 336
 Gly Asp Val Ile Gln Ala Leu Asp Ala Gln Thr Gly Asp Leu Ile Trp
 100 105 110
 55 gaa cac cgc cgc caa ctg ccc gcc gtc gcc acg cta aac gcc caa ggc 384
 Glu His Arg Arg Gln Leu Pro Ala Val Ala Thr Leu Asn Ala Gln Gly
 115 120 125

	gac cgc aag cgc ggc gtc gcc ctt tac ggc acg agc ctc tat ttc agc	432
	Asp Arg Lys Arg Gly Val Ala Leu Tyr Gly Thr Ser Leu Tyr Phe Ser	
	130 135 140	
5	tca tgg gac aac cat ctg atc gcg ctg gat atg gag acg ggc cag gtc	480
	Ser Trp Asp Asn His Leu Ile Ala Leu Asp Met Glu Thr Gly Gln Val	
	145 150 155 160	
10	gta ttc gat gtc gaa cgt gga tcg ggc gaa gac ggc ttg acc agt aac	528
	Val Phe Asp Val Glu Arg Gly Ser Gly Glu Asp Gly Leu Thr Ser Asn	
	165 170 175	
15	acc acg ggg ccg att gtc gcc aat ggc gtc atc gtc gcg ggt tcc acc	576
	Thr Thr Gly Pro Ile Val Ala Asn Gly Val Ile Val Ala Gly Ser Thr	
	180 185 190	
20	tgc caa tat tcg ccc tat gga tgc ttt atc tcg ggg cac gat tcc gcg	624
	Cys Gln Tyr Ser Pro Tyr Gly Cys Phe Ile Ser Gly His Asp Ser Ala	
	195 200 205	
	acg ggt gag gag ctg tgg cgc aac cac ttt atc ccg cag ccg ggc gaa	672
	Thr Gly Glu Glu Leu Trp Arg Asn His Phe Ile Pro Gln Pro Gly Glu	
	210 215 220	
25	gag ggt gac gag act tgg ggc aat gat ttc gag gcg cgc tgg atg acc	720
	Glu Gly Asp Glu Thr Trp Gly Asn Asp Phe Glu Ala Arg Trp Met Thr	
	225 230 235 240	
30	ggc gtc tgg ggt cag atc acc tat gat ccc gtg acg aac ctt gtg ttc	768
	Gly Val Trp Gly Gln Ile Thr Tyr Asp Pro Val Thr Asn Leu Val Phe	
	245 250 255	
35	tat ggc tcg acc ggc gtg ggc cca gcg tcc gaa acc cag cgc ggc acg	816
	Tyr Gly Ser Thr Gly Val Gly Pro Ala Ser Glu Thr Gln Arg Gly Thr	
	260 265 270	
40	ccg ggc ggc acg ctg tat ggc acc aac acc cgc ttt gcg gtg cgt ccc	864
	Pro Gly Gly Thr Leu Tyr Gly Thr Asn Thr Arg Phe Ala Val Arg Pro	
	275 280 285	
	gac acg ggc gag att gtc tgg cgt cac cag acc ctg ccg cgc gac aac	912
	Asp Thr Gly Glu Ile Val Trp Arg His Gln Thr Leu Pro Arg Asp Asn	
	290 295 300	
45	tgg gac caa gaa tgc acg ttc gag atg atg gtc gcc aac gtc gat gtg	960
	Trp Asp Gln Glu Cys Thr Phe Glu Met Met Val Ala Asn Val Asp Val	
	305 310 315 320	
50	caa ccc tcg gcc gag atg gag ggt ctg cgc gcc atc aac ccc aat gcg	1008
	Gln Pro Ser Ala Glu Met Glu Gly Leu Arg Ala Ile Asn Pro Asn Ala	
	325 330 335	
55	gcg acg ggc gag cgc cgt gtg ctg acg ggt gcg cct tgc aag acc ggc	1056
	Ala Thr Gly Glu Arg Arg Val Leu Thr Gly Ala Pro Cys Lys Thr Gly	
	340 345 350	
60	acg atg tgg tcg ttt gat gcg gcc tcg ggc gaa ttc ctg tgg gcg cgt	110
	Thr Met Trp Ser Phe Asp Ala Ala Ser Gly Glu Phe Leu Trp Ala Arg	
	355 360 365	
	gat acc aac tac acc aat atg atc gcc tcg atc gac gag acc ggc ctt	1152
	Asp Thr Asn Tyr Thr Asn Met Ile Ala Ser Ile Asp Glu Thr Gly Leu	
	370 375 380	

5	gtg acg gtg aac gag gat gcg gtg ctg aaa gag ctg gac gtt gaa tat 1200 Val Thr Val Asn Glu Asp Ala Val Leu Lys Glu Leu Asp Val Glu Tyr 400 385 390 395
10	gac gtc tgc ccg acc ttc ctg ggt ggg cgc gac tgg tcg tca gcc gca 1248 Asp Val Cys Pro Thr Phe Leu Gly Gly Arg Asp Trp Ser Ser Ala Ala 415 405 410
15	ctg aac ccg gac acc ggc att tac ttc ttg ccg ctg aac aat gcc tgc 1296 Leu Asn Pro Asp Thr Gly Ile Tyr Phe Leu Pro Leu Asn Asn Ala Cys 430 420 425
20	tac gat att atg gcc gtt gat caa gag ttt agc gcg ctc gac gtc tat 1344 Tyr Asp Ile Met Ala Val Asp Gln Glu Phe Ser Ala Leu Asp Val Tyr 445 435 440
25	aac acc agc gcg acc gca aaa ctc gcg ccg ggc ttt gaa aat atg ggc 1392 Asn Thr Ser Ala Thr Ala Lys Leu Ala Pro Gly Phe Glu Asn Met Gly 460 450 455
30	cgc atc gac gcg att gat atc agc acc ggg cgc acc ttg tgg tcg gcg 1440 Arg Ile Asp Ala Ile Asp Ile Ser Thr Gly Arg Thr Leu Trp Ser Ala 480 465 470 475
35	gag cgc cct gcg gcg aac tac tcg ccc gtt ttg tcg acg gca ggc ggt 1488 Glu Arg Pro Ala Ala Asn Tyr Ser Pro Val Leu Ser Thr Ala Gly Gly 495 485 490
40	gtg gtg ttc aac ggc ggg acc gac cgc tat ttc cgt gcc ctc agc cag 1536 Val Val Phe Asn Gly Gly Thr Asp Arg Tyr Phe Arg Ala Leu Ser Gln 510 500 505
45	gaa acc ggc gag act ttg tgg cag gcc cgt ctt gcg acg gtc gcg acg 1584 Glu Thr Gly Glu Thr Leu Trp Gln Ala Arg Leu Ala Thr Val Ala Thr 525 515 520
50	ggg cag gcg atc agc tac gag ttg gac ggc gtg caa tat atc gcc atc 1632 Gly Gln Ala Ile Ser Tyr Glu Leu Asp Gly Val Gln Tyr Ile Ala Ile 540 530 535
55	ggt gcg ggc ggt ctg acc tat ggc acg caa ttg aac gcg ccg ctg gcc 1680 Gly Ala Gly Gly Leu Thr Tyr Gly Thr Gln Leu Asn Ala Pro Leu Ala 560 545 550 555
60	gag gca atc gat tcg acc tcg gtc ggt aat gcg atc tat gtc ttt gca 1728 Glu Ala Ile Asp Ser Thr Ser Val Gly Asn Ala Ile Tyr Val Phe Ala 575 565 570
65	ctg ccg cag taa 1740 Leu Pro Gln
70	<210> 2 <211> 579 <212> PRT <213> Gluconobacter oxydans
75	<400> 2

Met Asn Pro Thr Thr Leu Leu Arg Thr Ser Ala Ala Val Leu Leu Leu
1 5 10 15

Thr Ala Pro Ala Ala Phe Ala Gln Val Thr Pro Ile Thr Asp Glu Leu
 20 25 30
 5
 Leu Ala Asn Pro Pro Ala Gly Glu Trp Ile Asn Tyr Gly Arg Asn Gln
 35 40 45
 10
 Glu Asn Tyr Arg His Ser Pro Leu Thr Gln Ile Thr Ala Asp Asn Val
 50 55 60
 15
 Gly Gln Leu Gln Leu Val Trp Ala Arg Gly Met Glu Ala Gly Ala Val
 65 70 75 80
 20
 Gln Val Thr Pro Met Ile His Asp Gly Val Met Tyr Leu Ala Asn Pro
 85 90 95
 25
 Gly Asp Val Ile Gln Ala Leu Asp Ala Gln Thr Gly Asp Leu Ile Trp
 100 105 110
 30
 Glu His Arg Arg Gln Leu Pro Ala Val Ala Thr Leu Asn Ala Gln Gly
 115 120 125
 35
 Asp Arg Lys Arg Gly Val Ala Leu Tyr Gly Thr Ser Leu Tyr Phe Ser
 130 135 140
 40
 Ser Trp Asp Asn His Leu Ile Ala Leu Asp Met Glu Thr Gly Gln Val
 145 150 155 160
 45
 Val Phe Asp Val Glu Arg Gly Ser Gly Glu Asp Gly Leu Thr Ser Asn
 165 170 175
 50
 Thr Thr Gly Pro Ile Val Ala Asn Gly Val Ile Val Ala Gly Ser Thr
 180 185 190
 55
 Cys Gln Tyr Ser Pro Tyr Gly Cys Phe Ile Ser Gly His Asp Ser Ala
 195 200 205
 60
 Thr Gly Glu Glu Leu Trp Arg Asn His Phe Ile Pro Gln Pro Gly Glu
 210 215 220
 65
 Glu Gly Asp Glu Thr Trp Gly Asn Asp Phe Glu Ala Arg Trp Met Thr
 225 230 235 240
 70
 Gly Val Trp Gly Gln Ile Thr Tyr Asp Pro Val Thr Asn Leu Val Phe
 245 250 255
 Tyr Gly Ser Thr Gly Val Gly Pro 4/6 a Ser Glu Thr Gln Arg Gly Thr

260

265

270

5 Pro Gly Gly Thr Leu Tyr Gly Thr Asn Thr Arg Phe Ala Val Arg Pro
 275 280 285

10 Asp Thr Gly Glu Ile Val Trp Arg His Gln Thr Leu Pro Arg Asp Asn
 290 295 300

15 Trp Asp Gln Glu Cys Thr Phe Glu Met Met Val Ala Asn Val Asp Val
 305 310 315 320

Gln Pro Ser Ala Glu Met Glu Gly Leu Arg Ala Ile Asn Pro Asn Ala
 325 330 335

20 Ala Thr Gly Glu Arg Arg Val Leu Thr Gly Ala Pro Cys Lys Thr Gly
 340 345 350

25 Thr Met Trp Ser Phe Asp Ala Ala Ser Gly Glu Phe Leu Trp Ala Arg
 355 360 365

30 Asp Thr Asn Tyr Thr Asn Met Ile Ala Ser Ile Asp Glu Thr Gly Leu
 370 375 380

Val Thr Val Asn Glu Asp Ala Val Leu Lys Glu Leu Asp Val Glu Tyr
 385 390 395 400

35 Asp Val Cys Pro Thr Phe Leu Gly Gly Arg Asp Trp Ser Ser Ala Ala
 405 410 415

40 Leu Asn Pro Asp Thr Gly Ile Tyr Phe Leu Pro Leu Asn Asn Ala Cys
 420 425 430

45 Tyr Asp Ile Met Ala Val Asp Gln Glu Phe Ser Ala Leu Asp Val Tyr
 435 440 445

50 Asn Thr Ser Ala Thr Ala Lys Leu Ala Pro Gly Phe Glu Asn Met Gly
 450 455 460

Arg Ile Asp Ala Ile Asp Ile Ser Thr Gly Arg Thr Leu Trp Ser Ala
 465 470 475 480

55 Glu Arg Pro Ala Ala Asn Tyr Ser Pro Val Leu Ser Thr Ala Gly Gly
 485 490 495

60 Val Val Phe Asn Gly Gly Thr Asp Arg Tyr Phe Arg Ala Leu Ser Gln
 500 505 510

Glu Thr Gly Glu Thr Leu Trp Gln Ala Arg Leu Ala Thr Val Ala Thr
515 520 525

5 Gly Gln Ala Ile Ser Tyr Glu Leu Asp Gly Val Gln Tyr Ile Ala Ile
530 535 540

10 Gly Ala Gly Gly Leu Thr Tyr Gly Thr Gln Leu Asn Ala Pro Leu Ala
545 550 555 560

Glu Ala Ile Asp Ser Thr Ser Val Gly Asn Ala Ile Tyr Val Phe Ala
565 570 575
15

Leu Pro Gln

20

INTERNATIONAL SEARCH REPORT

Internati
PCT
Application No
03/10489

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12P17/04 C12P7/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, EMBASE, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 242 233 B1 (SUGISAWA TERUhide ET AL) 5 June 2001 (2001-06-05) table 1B	9
Y	column 10, line 11 - line 16; claim 5; table 1B	3,4,10
Y	EP 0 832 974 A (HOFFMANN LA ROCHE) 1 April 1998 (1998-04-01) SEQ ID NO:8 page 2, line 1 - line 2 claims 1,15-19; examples 4,8-11; table 10	1-8,10
Y	EP 0 911 415 A (HOFFMANN LA ROCHE) 28 April 1999 (1999-04-28) examples 2,3	1,2,5-8
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

9 February 2004

Date of mailing of the international search report

16/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gruber, A

INTERNATIONAL SEARCH REPORT

Internal

Publication No

PC

03/10489

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SAITO Y ET AL: "CLONING OF GENES CODING FOR L-SORBOSE AND L-SORBOSONE DEHYDROGENASES FROM GLUCONOBACTER OXYDANS AND MICROBIAL PRODUCTION OF 2-KETO-L-GULONATE, A PRECURSOR OF L-ASCORBIC ACID, IN A RECOMBINANT G. OXYDANS STRAIN" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 63, no. 2, 1997, pages 454-460, XP000886144 ISSN: 0099-2240 page 455, right-hand column, paragraph 4; table 1	1-4, 8-10
A	----- SUGISAWA T ET AL: "ISOLATION AND CHARACTERIZATION OF A NEW VITAMIN C PRODUCING ENZYME (L-GULONO-GAMMA-LACTONE DEHYDROGENASE) OF BACTERIAL ORIGIN" BIOSCIENCE, BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 59, no. 2, February 1995 (1995-02), pages 190-196, XP001084987 ISSN: 0916-8451 page 191, right-hand column, paragraph 3	1, 2, 5-8
A	----- MACAULEY S ET AL: "THE GENUS GLUCONOBACTER AND ITS APPLICATIONS IN BIOTECHNOLOGY" CRC CRITICAL REVIEWS IN BIOTECHNOLOGY, CRC PRESS, BOCA RATON, FL, US, vol. 21, no. 1, 2001, pages 1-25, XP008026977 ISSN: 0738-8551 page 12, left-hand column, paragraph 1 -page 18, left-hand column, paragraph 1	1, 2, 8
A	----- HANCOCK R D ET AL: "Biotechnological approaches for l-ascorbic acid production" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 20, no. 7, 1 July 2002 (2002-07-01), pages 299-305, XP004361398 ISSN: 0167-7799 page 300, left-hand column, paragraph 2 -page 301, left-hand column, paragraph 1 ----- -/--	1, 2, 8

INTERNATIONAL SEARCH REPORT

Internat

pplication No

PC

03/10489

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BOUDRANT J: "MICROBIAL PROCESSES FOR ASCORBIC ACID BIOSYNTHESIS: A REVIEW" ENZYME AND MICROBIAL TECHNOLOGY, STONEHAM, MA, US, vol. 12, no. 5, 1 May 1990 (1990-05-01), pages 322-329, XP000646789 ISSN: 0141-0229 page 323, left-hand column, paragraph 3 -page 325, left-hand column, paragraph 2 -----</p>	1,2,8

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern:

Application No

PC

03/10489

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6242233	B1	05-06-2001	BR 9805685 A CA 2253023 A1 CN 1225390 A EP 0922759 A2 IN 187978 A1 JP 11225754 A US 2001026933 A1	11-04-2000 01-06-1999 11-08-1999 16-06-1999 03-08-2002 24-08-1999 04-10-2001
EP 0832974	A	01-04-1998	EP 0832974 A2 BR 9704748 A CN 1183472 A JP 10229885 A	01-04-1998 10-11-1998 03-06-1998 02-09-1998
EP 0911415	A	28-04-1999	EP 0476442 A2 EP 0911415 A2 AT 180831 T CN 1060111 A , B CN 1274756 A DE 69131286 D1 DE 69131286 T2 DK 476442 T3 JP 3086301 B2 JP 4281785 A US 5250428 A	25-03-1992 28-04-1999 15-06-1999 08-04-1992 29-11-2000 08-07-1999 11-11-1999 15-11-1999 11-09-2000 07-10-1992 05-10-1993